Drug delivery systems to prevent peritoneal metastasis after surgery of digestives or ovarian carcinoma: A review.
Drug delivery system
Hydrogel
Microparticle
Nanoparticle
Peritoneal metastasis
Thermogel
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
05 Jan 2021
05 Jan 2021
Historique:
received:
15
07
2020
revised:
28
10
2020
accepted:
29
10
2020
pubmed:
7
11
2020
medline:
22
6
2021
entrez:
6
11
2020
Statut:
ppublish
Résumé
Peritoneum represents a frequent site of metastasis especially for digestive and ovarian primary cancers. The conventional approach to treat peritoneal metastasis consists in systemic chemotherapy, but the median survival associated is only a few months. Recent therapeutic developments result in an aggressive strategy associating cytoreductive surgery (CRS) and hyperthermic intra peritoneal chemotherapy (HIPEC). However, a recent study failed to show an improvement in the overall survival and relapse free survival of this combo in comparison to CRS alone. Confronted to a lack of guidelines, several drug delivery systems (DDS) had been developed and tested in animal models to offer an effective easy-to-use solution for surgeons to prevent peritoneal metastasis. In this work, we reviewed most of the strategies used to treat peritoneal metastasis (PM) from digestive or ovarian origin and concentrated on 3 different DDS strategies: particulates DDS, non particulates DDS (including implants, films and gels) and combination of both (in particular hydrogels loaded with particles).
Identifiants
pubmed: 33157213
pii: S0378-5173(20)31026-7
doi: 10.1016/j.ijpharm.2020.120041
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
120041Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.